Pathstone Family Office’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Pathstone Family Office’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-17,000	Closed	-$2.97K	–	1339
2023 Q1	$2.97K	Sell	17,000 -13,000	-43%	-$7.24K	﹤0.01%	1193
2022 Q4	$11.9K	Buy	30,000 +6,000	+25%	+$3.95K	﹤0.01%	1478
2022 Q3	$18.4K	Buy	24,000 +14,000	+140%	+$29.4K	﹤0.01%	1461
2022 Q2	$28.8K	Buy	+10,000	New	+$35.1K	﹤0.01%	1029

Pathstone Family Office's CDAK Position: Q2 2023 in Review

Pathstone Family Office sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2023, closing a stake of 17,000 shares — an estimated $2.97K sold.

Pathstone Family Office first reported a position in CDAK in Q2 2022 and held it in 4 quarters. The position peaked at $28.8K in Q2 2022. 1 fund tracked by Wall St. Rank holds CDAK as of Q2 2023.

Pathstone Family Office reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Pathstone Family Office sold 17,000 Codiak BioSciences, Inc. Common Stock shares in Q2 2023, an estimated $2.97K.
Pathstone Family Office first reported a position in Codiak BioSciences, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
Pathstone Family Office's Codiak BioSciences, Inc. Common Stock position peaked at $28.8K in Q2 2022.
1 fund tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2023.

Based on Pathstone Family Office's 13F filing for Q2 2023, filed 14 Aug 2023.